Travere Therapeutics is committed to research and development of new therapies for rare diseases.
Therapeutic area: HCU
Study type: Observational
Learn more: hcuconnection.com | NCT02998710
Therapeutic area: FSGS; IgAN
Study type: Phase 2
Learn more: eppikclinicalstudy.com | NCT05003986
Therapeutic area: IgAN
Study type: Phase 2
Learn more: NCT05856760
Investigational therapy: Pegtibatinase (TVT-058)
Therapeutic area: HCU
Study type: Interventional
Learn more: NCT06247085
In September 2024, Travere voluntarily paused the enrollment in the HARMONY Study due to commercial manufacturing scale-up. Read the press release>
Investigational therapy: Pegtibatinase (TVT-058)
Therapeutic area: HCU
Study type: Phase 1/2
Learn more: hcuconnection.com | NCT03406611
Investigational therapy: Sparsentan
Therapeutic area: FSGS
Study type: Phase 3
Learn more: NCT03493685
View a visual abstract of the DUPLEX Study results>
Investigational therapy: Sparsentan
Therapeutic area: IgAN
Study type: Phase 3
Learn more: NCT03762850
View a visual abstract of the PROTECT Study results>
Therapeutic area: FSGS; IgAN
Study type: Observational
Learn more: NCT05200871
View an infographic about the HONUS Study>